Jagsonpal Pharmaceuticals Limited announced its audited financial results for the quarter and year ended March 31, 2026. For the fourth quarter of FY26, the company reported a revenue of ₹64.2 crore (₹642 Mn), a 9.6% increase year-on-year, and a Profit After Tax (PAT) of ₹8.8 crore (₹88 Mn), up 31% YoY. The company's operating EBITDA stood at ₹10.6 crore (₹106 Mn) for the quarter. For the full fiscal year FY26, revenue grew by 6.9% to ₹287.2 crore (₹2,872 Mn), with operating EBITDA at ₹60.9 crore (₹609 Mn). PAT for FY26 increased by 19% to ₹44.6 crore (₹446 Mn). The company ended the fiscal year with a robust cash position of ₹191 crore (₹1,907 Mn). In a significant move for shareholder value, the Board has recommended a higher dividend distribution of 200% (including a 75% special dividend), amounting to approximately ₹26.2 crore (₹262 Mn). Furthermore, the company announced a proposed buyback of up to 16 lakh equity shares at ₹250 per share, with a total outlay of ₹40 crore. Promoters will not participate in this buyback. This strategic capital allocation is expected to improve ROCE from 22.0% to 25.7% and ROE from 16.2% to 18.9%.
